Treatment with DAPT, an inhibitor of the Notch-activating enzyme, ␥-secretase is known to reduce damage to ischemic brain. However, the molecular mechanisms supporting this therapeutic effect are not fully understood. Here we demonstrated that Notch/RBP-J signaling is activated in NG2 + glial progenitors and reactive astrocytes such as GFAP + cells, Nestin + cells and RC2 + cells, using Notch/RBP-J signaling reporter mice. 3-day DAPT treatment reduced the number of reactive astrocytes but not NG2 + glial progenitors. BrdU labeling experiments have shown that this reduction was due to decreased proliferation of reactive astrocytes. DAPT inhibited nuclear-translocation of Olig2, which is indispensable for proliferation and differentiation of reactive astrocytes. These findings suggest that Notch signaling might promote proliferation and differentiation of reactive astrocytes through the regulation of nucleo-cytoplasmic translocation of Olig2.
Introduction
Notch/RBP-J signaling has been known to regulate various aspects of neural cell fate specification (Androutsellis-Theotokis et al., 2006; de la Pompa et al., 1997; Fujimoto et al., 2009; Ohtsuka et al., 2001) . Notch is a cell-surface receptor. Ligand binding to Notch leads to its proteolytic clevages. The released intracellular domain translocates to the nucleus and upregulates the transcription of its target genes by interacting with a DNA-binding protein, RBP-J (Kato et al., 1997; Tamura et al., 1995) . This cleavage is accomplished by the ␥-secretase complex (Selkoe and Kopan, 2003) .
Reactive astrogliosis is a crucial response to brain injuries such as trauma, infection and ischemia. Reactive astrocytes generate from proliferating cells (Alonso, 2005) . Pulse-chase labeling experiments with 5-bromo-2 -deoxyuridine (BrdU) suggested that NG2 cells might be a source of reactive astrocytes. However, genetic fate mapping analysis suggested that most of reactive astrocytes differentiate from quiescent astrocytes, which resumes proliferation upon brain injury but not from NG2 cells (Buffo et al., 2008; Komitova et al., 2011) .
In culture of neural stem cells and glial progenitors, Olig2 inhibits astrocytic differentiation (Fukuda et al., 2004) and nucleo-cytoplasmic Olig2 translocation mediates differentiation of astrocytes (Magnus et al., 2007; Setoguchi and Kondo, 2004) . The translocation of Olig2 is also observed in brain-injuryinduced reactive astrogliogenesis in vivo (Magnus et al., 2007) , but astrocyte-specific conditional knockout studies have shown that Olig2 is indispensable for reactive astrocyte proliferation rather than inhibits their differentiation (Chen et al., 2008) . Notch signaling promotes astrocytic differentiation (Ge et al., 2002; Tanigaki et al., 2001 ) and Olig2 is a direct target of Notch signaling (Fujimoto et al., 2009) . Notch inhibition by a ␥-secretase inhibitor (GSI) decreases proliferation of reactive astrocytes after brain injury (Shimada et al., 2011) .
Here we examined the effects of Notch signaling on subpopulations of proliferating glial cells and localization of Olig2 in vivo after ischemic stroke. Our experiments have shown differential roles of Notch signaling in glial populations after ischemic stroke. Notch signaling upregulates Olig2 expression and promotes Olig2 localization in nucleus in GFAP-positive cells in reactive astrogliogenesis in vivo. (Longa et al., 1989) . Anesthesia was maintained using a mixture containing 1% halothane in 30% oxygen and 70% nitrous oxide. Rectal temperature was maintained at 37 C • with a thermostatcontrolled heating pad. After 60 min MCAO with a 8.0 nylon monofilament coated with silicon, the filament was withdrawn. Regional cerebral blood flows of the mice were measured with a laser-Doppler flowmetry (Omegawave, Tokyo, Japan) to confirm the induction of ischemia and reperfusion. After MCAO, the mice were placed in a thermally controlled incubator (32 • C) for 2 h. ␥-Secretase inhibitor, 100 mg/kg N-S-phenyl-glycine-t-butyl ester (DAPT) (Tocris, Bristol, UK) or dimethylsulfoxide (DMSO) (control) was injected subcateneously (s.c.) 3 h before MCAO and every 12 h after MCAO. DAPT was dissolved in DMSO (250 mg/ml) and diluted into a mixture of 5% EtOH and 95% corn oil to the final volume of 10 mL/kg.
BrdU labeling analysis
Mice were sacrificed 3 days after MCAO. They were intraperitoneally with BrdU (100 mg/kg) once 2 h before sacrifice. Mice were then perfused transcardially with 4% paraformaldehyde in PBS. Brains were fixed for 12 h in 4% PFA, then transferred to a 30% sucrose and were embedded in tissue-tek O. C. T. compound (Sakura Finetechnical, Tokyo, Japan) and cut at 40 m thickness. BrdU staining was performed as described previously (Handler et al., 2000) .
Immunohistochemistry of tissue sections
Mice were perfused and sectioned, as above. Immunohistochemical staining was performed with primary antibodies for 24 h at 4 • C after blocking for 1 h at room temperature with 5% donkey serum (Millipore, Billerica, USA). Then the sections were incubated for 1 h at room temperature with secondary antibodies (Molecular Probes, Eugene, USA). The primary antibodies used were anti-BrdU (BU1/75, Oxford Biotechnology, Oxfordshire, UK), anti-PSA-NCAM (Millipore), anti-Dlx2 (Millipore), anti-GFAP (DAKO, Glostrup, Denmark, BD Biosciences Immunocytometry Systems, San Jose, CA, USA), anti-Olig2 (IBL, Gunma, Japan), anti-Nestin (Millipore, BD Biosciences Immunocytometry Systems), anti-RC-2 (Millipore), anti-NG2 (Millipore), anti-active Caspase3 (Promega, Madison, WI, USA), anti-Hes1 (Abcam, Cambridge, MA, USA) antibodies. Slides were examined with an Olympus confocal laser scanning microscope (FV-300, Olympus, Tokyo, Japan).
Generation of transgenic mice
4x RBP-J-binding sites, SV40 promoter and Venus were subcloned between the mouse H19 insulators of pWHERE (Invivogen, SanDiego, CA, USA). This Notch signaling reporter was used to generate Notch/RBP-J signaling reporter mouse line (RBRC03783) by RIKEN Bioresource Center through the National Bio-resource Project of the MEXT, Japan. This mouse line is maintained and distributed by RIKEN Bioresource Center. All mice were maintained in accordance with the Committee on Animal Research at Research Institute, Shiga Medical Center. Fig. 2 . Reporter gene expression was observed in the cortical peri-infarct region of the Notch signaling reporter transgenic mice after stroke. Immunohistochemical analysis of Venus (green), GFAP (red), Nestin (red), NG2 (red), Olig2 (red) and DAPI (blue) 24 h after MCAO. Scale bar = 10 m.
Results

Notch signaling is activated in glial cells after ischemic-reperfusion
To characterize endogenous Notch/RBP-J signaling activation after stroke, we generated a transgenic Notch reporter line, which express Venus under an artificial Notch/RBP-J-responsive promoter with four RBP-J binding sites and basal simian virus 40 (SV40) promoter (Fujimoto et al., 2009; Mizutani et al., 2007) (Fig. 1A) . A Venus is a GFP derivative with 10 fold strong fluorescence than YFP (Nagai et al., 2002) . We first confirmed the reporter's specificity to Notch/RBP-J signal activation by examining Venus expression in normal adult subventricular zone (SVZ) of Notch reporter mice. As previously reported, Venus was expressed in GFAP-positive B cells and Dlx2-positive C cells but not in PSA-NCAM-positive A cells (Andreu-Agullo et al., 2009) (Fig. 1B) and this Venus expression was downregulated by a ␥-secretase inhibitor (GSI), DAPT (N-[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenyl-glycine t-butyl ester) treatment (data not shown). The expression of Hes1, a wellknown target of Notch signaling was observed in Venus-positive cells (Fig. 1B) . Next, to examine which type of glial cells show Notch activation in generation of reactive astrocytes, we performed middle cerebral artery occlusion (MCAO) in Notch reporter mice. Venus expression was enhanced in B cells and C cells in the SVZ with concomitant increased level of Hes1 expression 24 h after MCAO, as previously reported (Wang et al., 2009) (Fig. 1C) . Ischemic stroke induced Venus expression both in peri-infarct and infarct regions. Immunohistochemical analysis of peri-infarct area showed that Venus was expressed in 16.9 ± 2.3% of GFAP-positive cells, 45.3 ± 9.3% Nestin-positive cells and 23.3 ± 10.5% NG2-positive cells 24 h after ischemia (Fig. 2) .
-Secretase inhibitor treatment decreased proliferation of reactive astrocyte but not NG2 + Cells
To examine whether Notch/RBP-J signaling is involved in glial responses after ischemia, we administrated DAPT 100 mg/kg s.c. twice a day for 3 days after ischemia. GSI treatment drastically reduced the numbers of GFAP + cells, Nestin + cells and RC2 + cells but not NG2 + cells in the peri-infarct area (GFAP + cells: DAPT, 1.5 ± 0.3 × 10 −3 cells/m 2 , DMSO, 2.1 ± 0.02 × 10 −3 cells/m 2 , n = 3, P = 0.049; Nestin + cells: DAPT, 6.6 ± 2.2 × 10 −4 cells/m 2 , DMSO, 1.2 ± 0.2 × 10 −3 cells/m 2 , n = 3, P = 0.041; RC2 + cells: DAPT, 3.5 ± 0.8 × 10 −4 cells/m 2 , DMSO, 6.1 ± 1.2 × 10 −4 cells/m 2 , n = 3, P = 0.034; NG2 + cells: DAPT, 6.3 ± 1.4 × 10 −4 cells/m 2 , DMSO, 5.3 ± 2.1 × 10 −4 cells/m 2 , n = 3, P = 0.52 (Student's t test)) ( Fig. 3A-C) . Next, to get further insight into the mechanism of reduced number of reactive astrocytes, we performed bromodeoxyuridine (BrdU) labeling experiments. BrdU was administrated once 2 h before sacrifice 3 days after ischemia. The number of BrdU + cells decreased in GFAP + cells but not in Nestin + cells (GFAP + cells: DAPT, 9.5 ± 1.2 × 10 −5 cells/m 2 , DMSO, 2.0 ± 0.6 × 10 −4 cells/m 2 , n = 3, P = 0.046; Nestin + cells: DAPT, 3.2 ± 3.1 × 10 −5 cells/m 2 , DMSO, 5.3 ± 6.1 × 10 −5 cells/m 2 , n = 3, P = 0.63 (Student's t test)) ( Fig. 3D-F) . Finally, we examined apoptotic cells 3 days after stroke. Majority of active-Caspase3 positive apoptotic cells existed in infarcted core regions and few were detected in the peri-infarct area, which was not affected by GSI treatment (Fig. 3D) . These findings suggest the GSI-induced reduced number of GFAP + cells is caused by proliferation deficits of GFAP + cells.
-Secretase inhibitor treatment changed the localization of Olig2 in reactive astrocytes
Olig2 inhibits astrocyte differentiation from neural stem cells, and translocation of Olig2 from nucleus to cytoplasm promotes astrocytic differentiation in vitro (Fukuda et al., 2004; Setoguchi and Kondo, 2004) . GSI prevents astrocyte differentiation of perinatal A2B5 glial progenitors by inhibiting cytoplasmic translocation of Olig2 (Magnus et al., 2007) . To determine whether GSI affects radial glial proliferation through the regulation of Olig2 localization in vivo, we examined Olig2 localization in reactive astrocytes of 3-day GSI treated mice after ischemia. GSI treatment decreased the number of GFAP + nuclear-Olig2 + cells, GFAP + Olig2 − cells and Nestin + nuclear-Olig2 + cells (GFAP + nuclear-Olig2 + cells: DAPT, 1.9 ± 0.7 × 10 −4 cells/m 2 , DMSO, 1.0 ± 0.2 × 10 −3 cells/m 2 , n = 3, P = 0.0057; GFAP + Olig2 − cells: DAPT, 2.8 ± 0.9 × 10 −4 cells/m 2 , DMSO, 9.5 ± 1.9 × 10 −4 cells/m 2 , n = 3, P = 0.0051; Nestin + nuclear-Olig2 + cells: DAPT, 4.3 ± 1.8 × 10 −5 cells/m 2 , DMSO, 1.6 ± 0.3 × 10 −4 cells/m 2 , n = 3, P = 0.0055 (Student's t test)) ( Fig. 4A and B ). These observations indicated that GSI has an opposite effect on Olig2 localization in reactive astrocyte differentiation in ischemic brains in vivo compared to that in astrocytic differentiation in vitro.
Discussion
In this study, we showed that Notch/RBP-J signaling is activated both in NG2 + glial progenitors and reactive astrocytes in ischemic brains. GSI treatment significantly reduced proliferation and differentiation of GFAP + reactive astrocytes, as previously reported (Shimada et al., 2011) . The number of RC2 + and Nestin + reactive astrocytes also decreased but not the number of NG2 + cells. It has been reported that NG2 + cells provide a permissive environment for regenerating axon, whereas reactive astrocytes produce chondroitin sulfate proteoglycans inhibitory to axonal growth (Busch et al., 2010; Silver and Miller, 2004) . These differential effects of GSI on reactive astrocytes and NG2 + cells might be partially responsible for its beneficial effects on ischemic brain injury.
Reactive astrocytes are known to be composed of heterogeneous cell populations with distinct reactive astrocyte marker expressions. The expressions of Nestin and RC2 are restricted to peri-infarct region, whereas GFAP expression was found in astrocytes more distal to the infarct region (Zamanian et al., 2012) . Almost all RC2-positive astrocytes express Nestin after stroke (Shimada et al., 2010) . Nestin is induced 24 h after stroke and returned to baseline 7 days after MCAO. In contrast, GFAP and Vimentin expression are more persistently elevated (Zamanian et al., 2012) . The similar inhibitory effects of GSI on RC2-positive and Nestin-positive cell proliferation are also consistent with these findings.
Recent genetic fate mapping studies have shown majority of reactive astrocytes generate from glutamate aspartate transporter (GLAST)-positive quiescent astrocytes rather than NG2 + cells (Buffo et al., 2008; Komitova et al., 2011) . Majority of NG2 + cells differentiate to mature oligodendrocytes even after brain injury (Komitova et al., 2011) . Furthermore, the analysis of cell-type specific conditional knockout of Olig2 demonstrated that Olig2 expression in astrocytes but not in NG2 + cells is essential for reactive astrocyte generation (Chen et al., 2008; Komitova et al., 2011) . All these finding and our data of differential effects of GSI on reactive astrocytes and NG2 + cells might represent a lineage difference between reactive astrocytes and NG2 + cells.
Our data also showed that GSI treatment inhibits nuclear translocation of Olig2 in reactive astrocytes. Previous reports demonstrated that nuclear Olig2 expression is observed in proliferating reactive astrocytes (Chen et al., 2008) . Olig2 localization deficits caused by GSI might be responsible for reduced proliferation of reactive astrocytes. We have previously shown that Notch/RBP-J signaling regulates expression level of Olig2 (Fujimoto et al., 2009; Ikawa et al., 2006) , which might affect the localization of Olig2.
Notch signaling is known to play pivotal roles in astrocyte differentiation at multi-developmental stages. Notch/RBP-J signaling promotes astrocytic differentiation from multipotent neural precursor cells (Ge et al., 2002; Tanigaki et al., 2001) . Notch activation induced RBP-J-mediated transcriptional upregulation of nuclear factor1, which demethylates astrocyte-specific-genes and enables astrocytic differentiation (Namihira et al., 2009 ). Adenovirusmediated and transgenic-mediated conditional knockout of RBP-J have demonstrated that RBP-J is indispensable for maintenance of GFAP astrocytes in adult SVZ, which are quiescent neural stem cells (Fujimoto et al., 2009; Imayoshi et al., 2010) .
Taken together, our data have shown that GSI decreased nuclear-translocation of Olig2 and reduced the proliferation of reactive astrocytes, but not affected NG2 + cells. These differential effects of GSI on glial development might partially explain its therapeutic effects on ischemic injury.
